Importantly, pitavastatin treatment significantly lowered liver tumor burden, improved liver architecture, and decreased PCNA+ proliferating hepatocytes compared with carrier control in HBV+DEN-treated WT mice at 8 months post-infection (Fig. 5a–e and Supplementary Fig. 7b). This evidence concerns the gene PCNA and infection.